| 0.23 -0.014 (-5.74%) | 12-07 15:58 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.35 |
1-year : | 0.41 |
| Resists | First : | 0.3 |
Second : | 0.35 |
| Pivot price | 0.27 |
|||
| Supports | First : | 0.23 |
Second : | 0.19 |
| MAs | MA(5) : | 0.25 |
MA(20) : | 0.28 |
| MA(100) : | 0.42 |
MA(250) : | 0.61 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 3.9 |
D(3) : | 7.9 |
| RSI | RSI(14): 34.4 |
|||
| 52-week | High : | 2.36 | Low : | 0.23 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ACON ] has closed above bottom band by 10.9%. Bollinger Bands are 40.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.26 - 0.26 | 0.26 - 0.27 |
| Low: | 0.24 - 0.24 | 0.24 - 0.24 |
| Close: | 0.24 - 0.24 | 0.24 - 0.25 |
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Fri, 01 Dec 2023
BioNexus Gene Lab (NASDAQ:BGLC) vs. Aclarion (NASDAQ:ACON) Financial Comparison - Defense World
Mon, 27 Nov 2023
Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams - Yahoo Finance
Wed, 25 Oct 2023
Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring ... - OrthoSpineNews
Tue, 19 Sep 2023
Why Elutia Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket - Avinger (NASDAQ - Benzinga
Fri, 08 Sep 2023
Aclarion appeals latest Nasdaq delisting notice – BizWest - BizWest
Mon, 28 Aug 2023
Aclarion cuts losses but delayed report shows continued financial stress – BizWest - BizWest
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Health Information Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 5.89e+006 (%) |
| Held by Institutions | 32.3 (%) |
| Shares Short | 61 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.53e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 95.8 % |
| Return on Equity (ttm) | -104 % |
| Qtrly Rev. Growth | 84130 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 35330 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|